Following on from information provided to NICE by the company in [Rheumatoid arthritis (active, treated) – sirukumab, the appraisal of October 2017 was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1002
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Stakeholders
- Companies sponsors
- Janssen (sirukumab)
- Others
- Department of Health
- NHS England
- Welsh Government
- Patient carer groups
- Arthritis Action
- National Rheumatoid Arthritis Society
- Professional groups
- British Society for Rheumatology
- Primary Care Rheumatology Society
- Royal College of Physicians
- UK Clinical Pharmacy Association
- Comparator companies
- AbbVie
- Accord Healthcare - (CAU not returned, not participating)
- Amdipharm Mercury - (CAU not returned, not participating)
- Biogen
- Bristol-Myers Squibb
- Concordia international - (CAU not returned, not participating)
- Eli Lilly
- Hameln pharmaceuticals - (CAU not returned, not participating)
- Hospira - (CAU not returned, not participating)
- medac - (CAU not returned, not participating)
- Merck Sharp & Dohme
- Napp
- Nordic Pharma - (CAU not returned, not participating)
- Orion Pharma - (CAU not returned, not participating)
- Pfizer
- Roche
- Rosemont Pharmaceuticals - (CAU not returned, not participating)
- Sandoz - (CAU not returned, not participating)
- UCB Pharma Limited
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Welsh Health Specialised Services Committee
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in [Rheumatoid arthritis (active, treated) – sirukumab, the appraisal of October 2017 was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 30 October 2017 | Suspended. We have been informed by the company, Janssen, that it has decided to withdraw its marketing authorisation application for sirukumab. Consequently, we have suspended this appraisal. |
| 28 July 2017 | Invitation to participate |
| 25 April 2017 | Referral |
| 21 April 2017 | In progress. Topic referred |
| 03 January 2017 - 31 January 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual